HC Wainwright Predicts uniQure’s Q3 Earnings (NASDAQ:QURE)

uniQure N.V. (NASDAQ:QURE) – Analysts at HC Wainwright reduced their Q3 2026 EPS estimates for uniQure in a research note issued to investors on Thursday, July 30th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings per share of ($0.90) for the quarter, down from their previous forecast of ($0.84). HC Wainwright currently has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for uniQure’s Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($3.98) EPS, Q1 2027 earnings at ($1.04) EPS, Q2 2027 earnings at ($1.07) EPS, Q3 2027 earnings at ($0.95) EPS, Q4 2027 earnings at ($0.81) EPS, FY2027 earnings at ($3.87) EPS, FY2028 earnings at ($1.07) EPS, FY2029 earnings at $1.95 EPS and FY2030 earnings at $5.07 EPS.

A number of other brokerages also recently issued reports on QURE. Wells Fargo & Company upped their price target on uniQure from $60.00 to $75.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Stifel Nicolaus set a $28.00 price objective on uniQure in a report on Tuesday, May 5th. Royal Bank Of Canada boosted their target price on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Leerink Partners upped their target price on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Finally, Mizuho raised their price target on shares of uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $65.00.

uniQure Stock Up 1.0%

uniQure stock opened at $44.06 on Monday. The firm has a market cap of $3.06 billion, a price-to-earnings ratio of -10.99 and a beta of 0.93. The stock has a fifty day simple moving average of $37.89 and a two-hundred day simple moving average of $26.43. uniQure has a 12 month low of $8.73 and a 12 month high of $71.50. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same period last year, the company posted ($0.69) earnings per share.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC purchased a new stake in uniQure in the third quarter worth about $50,000. Torren Management LLC purchased a new position in shares of uniQure during the 4th quarter valued at about $28,000. IFP Advisors Inc purchased a new position in shares of uniQure during the 4th quarter valued at about $48,000. Smartleaf Asset Management LLC bought a new position in shares of uniQure during the 4th quarter valued at approximately $48,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of uniQure by 42.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 906 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Jack Kaye sold 21,167 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total transaction of $982,995.48. Following the completion of the sale, the director owned 25,996 shares of the company’s stock, valued at $1,207,254.24. The trade was a 44.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the sale, the insider directly owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 433,229 shares of company stock valued at $17,944,799 in the last 90 days. 4.65% of the stock is owned by insiders.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.